Top

European Archives of Oto-Rhino-Laryngology

06-09-2024 | Thyroid Cancer | Head and Neck

Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics

Authors: Mustafa Alkaya, Ali Bayram, Mehmet Yaşar, Merve Doğan, Hümeyra Gençer

Published in: European Archives of Oto-Rhino-Laryngology

Abstract

Purpose

The present study aimed to assess Lipocalin-2 (LCN2) expression in patients with papillary thyroid cancer (PTC) and to compare it with multinodular goitre (MNG). We also investigated the correlation between LCN2 expression and clinicopathologic characteristics.

Methods

This retrospective study included 63 surgically treated adult patients with papillary carcinoma and 65 adult patients with a MNG. Age, gender, physical, radiological and histopathological examinations, and surgical data of the patients were extracted from the hospital records. Size, histological subtype, capsule invasion, multifocality, extrathyroidal extension (ETE), lymph node metastasis (LNM), and immunohistochemical (IHC) studies of the tumour were recorded from the final histopathological reports of patients with PTC. The patient groups were compared in terms of LCN2 expression. The relationships between LCN2 expression and clinicopathological and other IHC parameters were also evaluated in patients with PTC.

Results

LCN2 expression was significantly higher in the PTC group than in the control group. No significant correlation was demonstrated between LCN2 expression and the presence of multifocal disease, capsular invasion, vascular invasion, ETE, and LNM. There was a moderate positive correlation between LCN2 and human bone marrow endothelial cell marker-1 (HBME-1) expressions, however, no correlation was found between LCN2 and cytokeratin-19 (CK19), CD56, and galectin-3.

Conclusion

LCN2 expression may be a useful biomarker in differentiating benign and malignant lesions of the thyroid gland; however, its expression pattern may not be associated with clinicopathologic characteristics of the PTC and should be investigated in further studies with larger clinical samples.

Sang Y, Hu G, Xue J, Chen M, Hong S, Liu R (2024) Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer. Endocr Feb 14. https://doi.org/10.1007/s12020-024-03722-6Online ahead of print

Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, EUROCARE-5 Working Group et al (2017) Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer 77:140–152. https://doi.org/10.1016/j.ejca.2017.02.023CrossRefPubMed

Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, Simon CA, Embia OM, Angelos P, Kaplan EL, Schechter RB (2013) A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154(6):1436–1446. https://doi.org/10.1016/j.surg.2013.07.008CrossRefPubMed

Dong W, Horiuchi K, Tokumitsu H, Sakamoto A, Noguchi E, Ueda Y, Okamoto T (2019) Time-varying pattern of mortality and recurrence from papillary thyroid cancer: lessons from a long-term follow-up. Thyroid 29(6):802–808. https://doi.org/10.1089/thy.2018.0128CrossRefPubMed

Ma H, Xu S, Yan J, Zhang C, Qin S, Wang X, Li N (2014) The value of tumour markers in the diagnosis of papillary thyroid carcinoma alone and in combination. Pol J Pathol 65(3):202–209. https://doi.org/10.5114/pjp.2014.45782CrossRefPubMed

Celestino R, Nome T, Pestana A, Hoff AM, Gonçalves AP, Pereira L, Cavadas B, Eloy C, Bjøro T, Sobrinho-Simões M, Skotheim RI, Soares P (2018) CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. BMC Cancer 18(1):68. https://doi.org/10.1186/s12885-017-3948-3CrossRefPubMedPubMedCentral

Lin HH, Liao CJ, Lee YC, Hu KH, Meng HW, Chu ST (2011) Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci 7(1):74–86. https://doi.org/10.7150/ijbs.7.74CrossRefPubMedPubMedCentral

Chung IH, Wu TI, Liao CJ, Hu JY, Lin YH, Tai PJ, Lai CH, Lin KH (2016) Overexpression of lipocalin 2 in human cervical cancer enhances tumor invasion. Oncotarget 7(10):11113–11126. https://doi.org/10.18632/oncotarget.7096CrossRefPubMedPubMedCentral

Barresi V, Leni A, Tuccari G, Barresi G (2012) Neutrophil gelatinase-associated lipocalin (NGAL) immunohistochemical expression in follicular cell-derived thyroid tumors: a novel diagnostic tool? Histol Histopathol 27(3):329–336. https://doi.org/10.14670/HH-27.329CrossRefPubMed

10.

Roli L, Pecoraro V, Trenti T (2017) Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence. Int J Biol Markers 32(1):e53–e61. https://doi.org/10.5301/jbm.5000245CrossRefPubMed

11.

Perrier ND, Brierley JD, Tuttle RM (2018) Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 68(1):55–63. https://doi.org/10.3322/caac.21439CrossRefPubMed

12.

Lippi G, Meschi T, Nouvenne A, Mattiuzzi C, Borghi L (2014) Neutrophil gelatinase-associated lipocalin in cancer. Adv Clin Chem 64:179–219. https://doi.org/10.1016/b978-0-12-800263-6.00004-5CrossRefPubMed

13.

Celepli P, Bigat İ, Karabulut S, Celepli S, Hücümenoğlu S (2022) Evaluation of Lipocalin-2 and twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition. Ann Diagn Pathol 59:151973. https://doi.org/10.1016/j.anndiagpath.2022.151973CrossRefPubMed

14.

Rosignolo F, Sponziello M, Durante C, Puppin C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G (2016) Expression of PAX8 target genes in papillary thyroid carcinoma. PLoS ONE 11(6):e0156658. https://doi.org/10.1371/journal.pone.0156658CrossRefPubMedPubMedCentral

15.

Wang Y, Zeng TT (2014) Clinical significance of neutrophil gelatinase-associated lipocalin (NGAL) in colorectal cancer: a meta-analysis. Genet Mol Res 13(3):7102–7112. https://doi.org/10.4238/2014.February.21.11CrossRefPubMed

16.

Ruiz-Morales JM, Dorantes-Heredia R, Arrieta O, Chávez-Tapia NC, Motola-Kuba D (2015) Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in lung adenocarcinoma. Tumour Biol 36(5):3601–3610. https://doi.org/10.1007/s13277-014-2997-3CrossRefPubMed

17.

Volpe V, Raia Z, Sanguigno L, Somma D, Mastrovito P, Moscato F, Mellone S, Leonardi A, Pacifico F (2013) NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 98(1):228–235. https://doi.org/10.1210/jc.2012-2528CrossRefPubMed

18.

Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, Tell G, Salzano AM, Scaloni A, Vuttariello E, Chiappetta G, Formisano S, Leonardi A (2008) The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A 105(37):14058–14063. https://doi.org/10.1073/pnas.0710846105CrossRefPubMedPubMedCentral

Title: Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics
Authors: Mustafa Alkaya
Ali Bayram
Mehmet Yaşar
Merve Doğan
Hümeyra Gençer
Publication date: 06-09-2024
Publisher: Springer Berlin Heidelberg
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: European Archives of Oto-Rhino-Laryngology
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-024-08954-w

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content